In addition, pharmacologic inhibition of IFNGR and IL-6R signaling using balanced JAK1/JAK2 inhibitors, such as RUX or BARI, reduces GvHD, as observed in the recipient mice transplanted with Ifngr1−/− T cells along with anti-IL6R blocking antibody [12]. Here, JAK2 is linked to graft versus host disease.